Journal of bone oncology · 2016 · 78 citations · 22 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyTumor ProgressionBone MetastasisBone TumorsCancer BiomarkersMalignant NeoplasmsNoncoding Rna In CancerTumor InvasionCancer Metastasis BiomarkersDistant Metastasis DetectionMicrorna Function In CancerMicrorna In CancerMicrorna Prognostic MarkersMicrorna Regulation In CancerPrognostic Marker AssessmentSerum Biomarkers
BACKGROUND: MicroRNA-223 (miR-223) has been shown to be a potential diagnostic and prognostic marker for several cancers. In addition, miR-223 has been reported to suppress osteosarcoma cell proliferation in vitro. However, the clinical value of miR-223 is still unknown. METHODS: We detected the expression of miR-223 expression in the serum of osteosarcoma patients and in osteosarcoma cancer cells using RT-PCR. We compared the serum expression of miR-223 with the clinicopathological characteristics and survival of osteosarcoma patients. Finally, we explored the role of miR-223 on the invasion of osteosarcoma cancer cells using cell migration and invasion assays. RESULTS: We observed that the expression of miR-223 was significantly decreased in the serum of osteosarcoma patients and osteosarcoma cancer cells compared to healthy controls (P<0.01). Moreover, a receiver operating characteristic (ROC) curve analysis indicated that serum miR-223 is a potential diagnostic marker of osteosarcoma with an area under the ROC curve (AUC) of 0.956. Importantly, the patients with a lower expression of miR-223 tended to have distant metastasis (P<0.001) and a more advanced clinical stage (P<0.001). In addition, the survival time of patients with low miR-223 expression was significantly shorter compared to patients with high miR-223 expression (P<0.001). Furthermore, we found that miR-223 could inhibit the migration and invasion of osteosarcoma cells. CONCLUSIONS: miR-223 might be related to the metastasis of osteosarcoma and could be used as a potential diagnostic and prognostic biomarker in osteosarcoma.
22
Potential role of miR-9 and miR-223 in recurrent ovarian cancer
Alexandros Laios, Sharon O’Toole, Richard Flavin et al. · Molecular Cancer · 2008 · 301 citations · Full text
Medicine, Cancer Biology, Oncology +17
Bo–Sheng Li, Yongliang Zhao, Gang Guo et al. · PLoS ONE · 2012 · 242 citations · Full text